Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ruslan Grishanin"'
Autor:
Szilárd Kiss, Ruslan Grishanin, Aivan Nguyen, Romeo Rosario, Judith S. Greengard, Julio Nieves, Claire M. Gelfman, Mehdi Gasmi
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 18, Iss , Pp 345-353 (2020)
Several standard-of-care therapies for the treatment of retinal disease, including aflibercept, inhibit vascular endothelial growth factor (VEGFA). The main shortcoming of these therapies is potential undertreatment due to a lack of compliance result
Externí odkaz:
https://doaj.org/article/90238570e14b4903b4cc336b4e25c2c6
Autor:
Ruslan Grishanin, Pallavi Sharma, Szilard Kiss, Mehdi Gasmi, Claire M. Gelfman, Judith Greengard, Julio Nieves, Aivan Nguyen, Kristina Oresic Bender
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics
Inhibition of vascular endothelial growth factor is the mode of action for several approved therapies, including aflibercept, for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Lack of complianc
Autor:
Julio Nieves, Romeo J. Rosario, Szilard Kiss, Judith Greengard, Mehdi Gasmi, Aivan Nguyen, Ruslan Grishanin, Claire M. Gelfman
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 18, Iss, Pp 345-353 (2020)
Molecular Therapy. Methods & Clinical Development
Molecular Therapy. Methods & Clinical Development
Several standard-of-care therapies for the treatment of retinal disease, including aflibercept, inhibit vascular endothelial growth factor (VEGFA). The main shortcoming of these therapies is potential undertreatment due to a lack of compliance result
Autor:
Wenzheng Hu, Brian Vuillemenot, Annahita Keravala, Mehdi Gasmi, Szilard Kiss, Matthew Lawrence, Ruslan Grishanin, Judith Greengard, Mark Blumenkrantz, Claire M. Gelfman, Pallavi Sharma
Publikováno v:
Molecular Therapy
Inhibition of vascular endothelial growth factor, a key contributor to the choroidal neovascularization associated with wet age-related macular degeneration, is the mode of action of several approved therapies, including aflibercept, which requires f
Autor:
Mehdi Gasmi, Ruslan Grishanin, Pallavi Sharma, Julio Nieves, Szilard Kiss, Kelly Hanna, Aivan Nguyen, Kristina Oresic Bender, Romeo J. Rosario, Claire M. Gelfman, Judith Greengard
Publikováno v:
Translational Vision Science & Technology
Purpose To evaluate the long-term safety of vascular endothelial growth factor (VEGF) suppression with sustained aflibercept expression after a single intravitreal injection (IVI) of ADVM-022, an anti-VEGF gene therapy, in non-human primates (NHPs).
Autor:
Yik Andy Yeung, Catherine Bowes Rickman, Michael Landowski, Holly Dong, Ons Harrabi, Thomas Van Blarcom, Ruslan Grishanin, Daniel R. Saban, John R. Deans, Mikael Klingeborn, Christopher B. Toomey, Una Kelly, John C. Lin
Publikováno v:
Investigative Ophthalmology & Visual Science
Purpose A large body of evidence supports a central role for complement activation in the pathobiology of age-related macular degeneration (AMD), including plasma complement component 5a (C5a). Interestingly, C5a is a chemotactic agent for monocytes,